Table 5 The multiple logistics regression analysis of risk factors for MACE and Bleeding
Variables (%) | MACE (n = 101) | No-MACE (n = 250) | OR (95% CI) | P value | Bleeding (n = 18) | No-Bleeding (n = 333) | OR (95% CI) | P value |
|---|---|---|---|---|---|---|---|---|
Age > 65 | 23 (22.8) | 66 (26.4) | 0.767 (0.423–1.389) | 0.381 | 6 (33.3) | 83 (24.9) | 0.660 (0.203–2.150) | 0.491 |
BMI > 26 kg/m2 | 81 (80.2) | 178 (71.2) | 1.436 (0.795–2.595) | 0.230 | 9 (50) | 250 (75.1) | 2.615 (0.779–8.781) | 0.12 |
Smoking | 33 (32.7) | 108 (43.2) | 0.751 (0.418–1.351) | 0.340 | 6 (33.3) | 135 (40.5) | 1.218 (0.321–4.611) | 0.772 |
Alcohol intake | 65 (18.5) | 14 (13.9) | 0.475 (0.491- 0.766) | 0.491 | 2 (11.1) | 63 (18.9) | 1.894 (0.298–12.026) | 0.498 |
NSTEMI | 26 (25.7) | 30 (12.0) | 0.586 (0.238–1.443) | 0.245 | 3 (16.7) | 53 (15.9) | 0.298 (0.074–1.196) | 0.088 |
Hypertension | 57 (56.4) | 140 (56.0) | 1.147 (0.671–1.963) | 0.616 | 9 (50) | 190 (57.1) | 1.164 (0.323–4.193) | 0.817 |
Dyslipidemia | 77 (76.2) | 195 (78) | 1.029 (0.574–1.843) | 0.924 | 13 (72.2) | 259 (77.8) | 1.761 (0.582–5.323) | 0.316 |
Concomitant medication | ||||||||
 β-Blocker | 88 (87.1) | 199 (79.6) | 1.552 (0.79–3.046) | 0.202 | 12 (66.7) | 275 (82.6) | 2.181 (0.648–7.337) | 0.208 |
 ARB or ACEI | 73 (72.3) | 194 (77.6) | 0.637 (0.351–1.155) | 0.137 | 10 (55.6) | 257 (77.2) | 1.867 (0.534–6.531) | 0.328 |
 CYP2C19*2 carriers | 43 (42.6) | 57 (22.8) | 2.51 (1.534–4.09) | < 0.001* | 2 (11.1) | 98 (29.4) | 4.111 (0.440–37.414) | 0.215 |
 CYP2C19*17 carriers | 20 (19.8) | 79 (31.6) | 1.084 (0.331–3.549) | 0.893 | 8 (44.4) | 93 (27.9) | 0.171 (0.012–2.360) | 0.187 |
Metabolizer phenotype | ||||||||
 IMs | 43 (42.6) | 64 (25.6) | 1.829 (0.463–7.226) | 0.389 | 4 (22.2) | 103 (30.9) | 1.17 (0.158–8.652) | 0.878 |
 PMs | 7 (6.9) | 5 (2.0) | 3.643 (0.804–16.501) | 0.094 | / | 12 (3.6) | / | / |
 UMs | 14 (13.9) | 71 (28.4) | 0.477 (0.125–1.826) | 0.192 | 7 (38.9) | 78 (23.4) | 0.227 (0.012–4.262) | 0.322 |